Stockscreener 앱 받기
10.49
1.22%
-0.13
시간 외 거래:
10.69
0.20
+1.91%
전일 마감가:
$10.62
열려 있는:
$10.75
하루 거래량:
2.63M
Relative Volume:
0.99
시가총액:
$2.30B
수익:
$52.04M
순이익/손실:
$-290.50M
주가수익비율:
-7.2062
EPS:
-1.4557
순현금흐름:
$-240.94M
1주 성능:
-1.41%
1개월 성능:
+7.48%
6개월 성능:
+10.42%
1년 성능:
-17.85%
1일 변동 폭
$10.37
$10.94
1주일 범위
$10.37
$11.48
52주 변동 폭
$6.2301
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
명칭
Ocular Therapeutix Inc
전화
781-357-4000
주소
14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA
Compare OCUL vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
10.49 | 2.30B | 52.04M | -290.50M | -240.94M | -1.4557 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.39 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.97 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.77 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-15 | 개시 | Chardan Capital Markets | Buy |
| 2025-04-08 | 개시 | William Blair | Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-03-11 | 개시 | Needham | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-20 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-31 | 재개 | Piper Sandler | Overweight |
| 2024-02-09 | 개시 | BofA Securities | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-08-10 | 재개 | Berenberg | Buy |
| 2021-08-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-11-13 | 재확인 | Raymond James | Strong Buy |
| 2020-08-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-03 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2019-05-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-21 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-11-15 | 개시 | Raymond James | Strong Buy |
| 2018-09-07 | 개시 | Piper Jaffray | Overweight |
| 2017-10-24 | 개시 | Guggenheim | Buy |
| 2017-07-26 | 개시 | H.C. Wainwright | Buy |
| 2017-07-12 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-06-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-08-11 | 개시 | JMP Securities | Mkt Outperform |
| 2016-02-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | 개시 | Morgan Stanley | Overweight |
모두보기
Ocular Therapeutix Inc 주식(OCUL)의 최신 뉴스
OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda? - Stocktwits
OCUL News | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill
Ocular Therapeutix (OCUL): Faster Path To Approval Comes With Rising Costs - Yahoo Finance
Ocular Therapeutix (OCUL) COO sells shares to cover taxes - Stock Titan
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences - GlobeNewswire
Ocular Therapeutix Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Ocular Therapeutix (NASDAQ: OCUL) holder to sell 1,099 shares - Stock Titan
This Insider Has Just Sold Shares In Ocular Therapeutix - webull.com
Ocular Therapeutix Inc. (OCUL) Peer Comparison – Compare with Others - Value Research
Ocular Therapeutix CDO Peter Kaiser sells $32,686 of OCUL shares By Investing.com - Investing.com Nigeria
Ocular Therapeutix CEO Dugel sells $233,159 in shares By Investing.com - Investing.com Nigeria
Ocular Therapeutix CSO Heier sells $35,530 in stock - Investing.com
Ocular Therapeutix CSO Sanjay Nayak sells $20,449 in shares By Investing.com - Investing.com Nigeria
Ocular Therapeutix CSO Sanjay Nayak sells $20,449 in shares - Investing.com
Ocular Therapeutix CDO Peter Kaiser sells $32,686 of OCUL shares - Investing.com
Ocular Therapeutix (NASDAQ: OCUL) exec share sale covers RSU tax withholding - Stock Titan
Ocular Therapeutix (NASDAQ: OCUL) officer to sell 1,897 shares - Stock Titan
Ocular Therapeutix (NASDAQ: OCUL) insider plans 21,649-share sale - stocktitan.net
Why Ocular Therapeutix (OCUL) Is Up 10.4% After Q2 Beat And AXPAXLI Phase 3 Timeline Update - Yahoo Finance
META_TITLE_QUOTE - Yahoo Finance
Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL) - Yahoo Finance
Ocular (OCUL) EPS and Revenue: Profit Per Share Clears Its Benchmark in the Latest Session; Market Reaction: The Stock Ends Down 5.46% in the Available RecordPost-Announcement Reaction - vinanet.vn
Ocular (OCUL) Latest Quarter: The EPS Result Is Above Expectation in the Latest Session; Shares Move 6.54% Up on the DayAdjusted Earnings Analysis - vinanet.vn
Ocular Therapeutix (OCUL) Institutional Ownership 2026 - MarketBeat
Clear Street Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Why Is Ocular Therapeutix Stock Gaining Monday? - Sahm
OCUL Looks 134.8% Overvalued on GF Value™ - GuruFocus
OCUL Stock Climbs As FDA Clears Path For AXPAXLI NDA - StocksToTrade
OCUL Stock Climbs As FDA Path And Cash Runway De‑Risk Story - timothysykes.com
Ocular Therapeutix (NASDAQ:OCUL) Shares Gap UpShould You Buy? - MarketBeat
Why is Ocular Therapeutix stock rallying today? By Investing.com - Investing.com Canada
OCUL Looks 141.9% Overvalued on GF Value™ - GuruFocus
Ocular Therapeutix stock rises as rival’s wet AMD trial stumbles By Investing.com - Investing.com South Africa
Ocular Therapeutix stock rises as rival’s wet AMD trial stumbles - Investing.com
EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate - Stocktwits
(OCUL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Ocular Therapeutix (OCUL) Posts Wider Losses And Files Shelf Registration, Is It Still Undervalued? - Sahm
OCUL|Ocular Therapeutix Inc|Price:9.890|Chg%:-0.210 - TradingKey
Ocular Therapeutix (NASDAQ:OCUL) Raised to "Hold" at Zacks Research - MarketBeat
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Ocular Therapeutix’s New Policy Leader Gets an 85,000-Share Option - Stock Titan
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Dimensional Fund Advisors LP Takes $5.49 Million Position in Ocular Therapeutix, Inc. $OCUL - MarketBeat
Janus Henderson Group PLC Has $581,000 Holdings in Ocular Therapeutix, Inc. $OCUL - MarketBeat
The debate of durability in nAMD - Endpoints News
Ocular Therapeutix, Inc. $OCUL Shares Acquired by The Manufacturers Life Insurance Company - MarketBeat
Ocular Therapeutix (OCUL) Holds Steady Near $9.24 as Key Resistance Looms at $9.70Institutional Buy Signals - vinanet.vn
Does Ocular Therapeutix (OCUL) Pairing Flat Revenue With a New Shelf Point to a Shifting Funding Strategy? - Sahm
Ocular Therapeutix (NASDAQ:OCUL) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Ocular Therapeutix Inc (OCUL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
1.67%
자본화:
|
볼륨(24시간):